AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35273012 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants who maintained normal fasting plasma glucose (FPG) and normal 2-hour plasma glucose (2hPG) levels during follow-up)
Number of subjects: 223
Study 35273031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia
Number of subjects: 0
Study 35273031 — intervention group
Group type: COMPARATOR
Intervention: Exacerbation of COPD
Number of subjects: 0
Study 35273055 — intervention group
Group type: EXPERIMENTAL
Intervention: Caller-attended telephone interviews (n=375)
Number of subjects: 580
Study 35273055 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face surveys (n=205)
Number of subjects: 580
Study 35273055 — intervention group
Group type: EXPERIMENTAL
Intervention: Both modalities (phone and face-to-face)
Number of subjects: 580
Study 35273055 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone surveys
Number of subjects: 580
Study 35273988 — intervention group
Group type: EXPERIMENTAL
Intervention: Italian herb meal
Number of subjects: 0
Study 35273988 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumpkin spice meal
Number of subjects: 0
Study 35273988 — intervention group
Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 0
Study 35274209 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infusion combined with intrathecal morphine
Number of subjects: 0
Study 35274209 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine
Number of subjects: 0
Study 35274209 — intervention group
Group type: COMPARATOR
Intervention: Continuous wound infusion alone
Number of subjects: 0
Study 35274279 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Black weight gain cluster
Number of subjects: 283
Study 35274279 — intervention group
Group type: EXPERIMENTAL
Intervention: Black weight loss cluster
Number of subjects: 283
Study 35274386 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-owned fast-track protocols (PFTPs) during admission
Number of subjects: 222
Study 35274386 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PFTP)
Number of subjects: 222
Study 35274472 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation alterations in muscle of ICU patients
Number of subjects: 172
Study 35274490 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic heart failure (CHF) patients
Number of subjects: 566
Study 35274490 — intervention group
Group type: COMPARATOR
Intervention: Non-CHF patients (Control)
Number of subjects: 566
Study 35274490 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrEF patients
Number of subjects: 566
Study 35274490 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF patients
Number of subjects: 566
Study 35274490 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF patients
Number of subjects: 566
Study 35274490 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF patients (after multivariate adjustment)
Number of subjects: 566
Study 35274704 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR TKIs (erlotinib, gefitinib, afatinib, or osimertinib)
Number of subjects: 246
Study 35274704 — intervention group
Group type: COMPARATOR
Intervention: First-line chemotherapy
Number of subjects: 246
Study 35274704 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 246
Study 35274704 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation EGFR TKIs
Number of subjects: 246
Study 35274704 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes across mutation categories
Number of subjects: 246
Study 35274717 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in combination with capecitabine and oxaliplatin (CAPOX)
Number of subjects: 11
Study 35274722 — intervention group
Group type: EXPERIMENTAL
Intervention: D-0316 (50 mg)
Number of subjects: 84
Study 35274722 — intervention group
Group type: EXPERIMENTAL
Intervention: D-0316 (100 mg)
Number of subjects: 84
Study 35275019 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic gallium 68 imaging (details on dosage and duration not provided)
Number of subjects: 0
Study 35275071 — intervention group
Group type: EXPERIMENTAL
Intervention: Design A (System Usability Scale)
Number of subjects: 5
Study 35275071 — intervention group
Group type: EXPERIMENTAL
Intervention: Design B (System Usability Scale)
Number of subjects: 5
Study 35275071 — intervention group
Group type: EXPERIMENTAL
Intervention: Design A (Normative path deviation)
Number of subjects: 5
Study 35275071 — intervention group
Group type: EXPERIMENTAL
Intervention: Design B (Normative path deviation)
Number of subjects: 5
Study 35275071 — intervention group
Group type: EXPERIMENTAL
Intervention: Design A (Effectiveness)
Number of subjects: 5
Study 35275071 — intervention group
Group type: EXPERIMENTAL
Intervention: Design B (Effectiveness)
Number of subjects: 5
Study 35275084 — intervention group
Group type: EXPERIMENTAL
Intervention: Online parenting intervention
Number of subjects: 334
Study 35275084 — intervention group
Group type: COMPARATOR
Intervention: Staff-delivered parenting intervention
Number of subjects: 334
Study 35275108 — intervention group
Group type: EXPERIMENTAL
Intervention: DEPITAC questionnaire administered by nurses
Number of subjects: 274
Study 35275108 — intervention group
Group type: EXPERIMENTAL
Intervention: DEPITAC questionnaire
Number of subjects: 274
Study 35275599 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiated in Fiebig 1 acute HIV infection
Number of subjects: 0
Study 35275599 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy (ART) initiated in later Fiebig stages
Number of subjects: 0
Study 35275706 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 86
Study 35275706 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with nivolumab/ipilimumab boosts
Number of subjects: 86
Study 35275706 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with nivolumab/ipilimumab boosts at week 8
Number of subjects: 86
Study 35275734 — intervention group
Group type: EXPERIMENTAL
Intervention: Father-focused childhood obesity prevention program, details on dosage and duration not available
Number of subjects: 0
Study 35275884 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation for atrial fibrillation (AF)
Number of subjects: 929
Study 35276694 — intervention group
Group type: EXPERIMENTAL
Intervention: GZ17-6.02
Number of subjects: 0
Study 35276694 — intervention group
Group type: COMPARATOR
Intervention: Multi-kinase/PDGFRβ inhibitors
Number of subjects: 0
Study 35276694 — intervention group
Group type: COMPARATOR
Intervention: HDAC inhibitors
Number of subjects: 0
Study 35276889 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed formula (EHF) supplemented with two human milk oligosaccharides (HMO)
Number of subjects: 194
Study 35276889 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 194
Study 35277288 — intervention group
Group type: EXPERIMENTAL
Intervention: Biparametric magnetic resonance imaging (bpMRI)
Number of subjects: 0
Study 35277288 — intervention group
Group type: COMPARATOR
Intervention: Multiparametric MRI
Number of subjects: 0
Study 35277313 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in WIC into the third year
Number of subjects: 0
Study 35277313 — intervention group
Group type: COMPARATOR
Intervention: Participation in WIC in the first year only
Number of subjects: 0
Study 35277313 — intervention group
Group type: COMPARATOR
Intervention: Introduced to sugar-sweetened beverages in the first year
Number of subjects: 0
Study 35277313 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed longer
Number of subjects: 0
Study 35277335 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based quality improvement project designed to improve delivery of comprehensive women's health care
Number of subjects: 69
Study 35277335 — intervention group
Group type: EXPERIMENTAL
Intervention: Creation of separate clinical spaces for women
Number of subjects: 69
Study 35277335 — intervention group
Group type: EXPERIMENTAL
Intervention: Education to change patient harassing behavior
Number of subjects: 69
Study 35277335 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of environments of care
Number of subjects: 69
Study 35277389 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of CoronaVac vaccine
Number of subjects: 796
Study 35277410 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based performance arts programme (Stroke Odysseys)
Number of subjects: 75
Study 35277577 — intervention group
Group type: EXPERIMENTAL
Intervention: High CAD PRS
Number of subjects: 3800
Study 35277577 — intervention group
Group type: COMPARATOR
Intervention: Low CAD PRS
Number of subjects: 3800
Study 35277577 — intervention group
Group type: EXPERIMENTAL
Intervention: High CAD PRS (Statins)
Number of subjects: 3800
Study 35277577 — intervention group
Group type: COMPARATOR
Intervention: Low CAD PRS (Statins)
Number of subjects: 3800
Study 35277577 — intervention group
Group type: EXPERIMENTAL
Intervention: High CAD PRS (Non-statin)
Number of subjects: 3800
Study 35277577 — intervention group
Group type: COMPARATOR
Intervention: Low CAD PRS (Non-statin)
Number of subjects: 3800
Study 35277733 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (NT-proBNP)
Number of subjects: 2522
Study 35277733 — intervention group
Group type: EXPERIMENTAL
Intervention: high-sensitive Troponin T (hsTnT)
Number of subjects: 2522
Study 35277935 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic impact survey
Number of subjects: 2950
Study 35278000 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted next-generation sequencing using the new gene panel TGP-T-LBL with 84 candidate genes
Number of subjects: 46
Study 35278000 — intervention group
Group type: COMPARATOR
Intervention: Previous gene panel with 80 candidate genes
Number of subjects: 46
Study 35278571 — intervention group
Group type: EXPERIMENTAL
Intervention: V-index during AF
Number of subjects: 1711
Study 35278571 — intervention group
Group type: EXPERIMENTAL
Intervention: QTc
Number of subjects: 1711
Study 35278825 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 208
Study 35278845 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive genomic profiling (CGP) using Oncomine Comprehensive Assay Version 3, ThermoFisher
Number of subjects: 134
Study 35278845 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive genomic profiling (CGP)
Number of subjects: 134
Study 35278876 — intervention group
Group type: EXPERIMENTAL
Intervention: Early echocardiography performed by treating physicians
Number of subjects: 1359
Study 35278876 — intervention group
Group type: COMPARATOR
Intervention: No echocardiography
Number of subjects: 1359
Study 35278876 — intervention group
Group type: EXPERIMENTAL
Intervention: Early echocardiography in cardiac disease patients
Number of subjects: 1359
Study 35278876 — intervention group
Group type: EXPERIMENTAL
Intervention: Early echocardiography
Number of subjects: 1359
Study 35279084 — intervention group
Group type: EXPERIMENTAL
Intervention: RBX2660
Number of subjects: 142
Study 35279084 — intervention group
Group type: COMPARATOR
Intervention: Historical control (standard-of-care antibiotics)
Number of subjects: 142
Study 35279088 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP&WATCH instrument for early recognition of changes in resident condition
Number of subjects: 573
Study 35279088 — intervention group
Group type: EXPERIMENTAL
Intervention: ISBAR instrument for structured communication
Number of subjects: 573
Study 35279088 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERCARE nurses providing on-site geriatric support
Number of subjects: 573
Study 35279143 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg single-dose primaquine
Number of subjects: 157
Study 35279152 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel (standard of care chemotherapy)
Number of subjects: 10
Study 35279152 — intervention group
Group type: EXPERIMENTAL
Intervention: MYC/MAX dimerization inhibitor (10058-F4)
Number of subjects: 10
Study 35279152 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cell RNA sequencing
Number of subjects: 10
Study 35279152 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid biopsy CTC-derived xenograft (CDX) models
Number of subjects: 10
Study 35279271 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg pembrolizumab intravenously every 3 weeks for 6 months (eight cycles)
Number of subjects: 17
Study 35279417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status assessed by the CONUT score
Number of subjects: 14849
Study 35279417 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 14849
Study 35279805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 5
Study 35279805 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 5
Study 35279805 — intervention group
Group type: COMPARATOR
Intervention: Guselkumab
Number of subjects: 5
Study 35279805 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 5
Study 35279805 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 5
Study 35279811 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m²) administered as four weekly intravenous infusions
Number of subjects: 25
Study 35280363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg) combined with paclitaxel (135 mg) and cisplatin as neoadjuvant therapy.
Number of subjects: 0
Study 35280363 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy (nCRT) as the standard treatment under NCCN guidelines.
Number of subjects: 0
Study 35280476 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO support
Number of subjects: 65
Study 35280494 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic low anterior resection (RLAR)
Number of subjects: 0
Study 35280494 — intervention group
Group type: COMPARATOR
Intervention: Transanal total mesorectal excision (TaTME)
Number of subjects: 0
Study 35280494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RLAR and TaTME
Number of subjects: 0
Study 35280654 — intervention group
Group type: EXPERIMENTAL
Intervention: ELIGARD
Number of subjects: 106
Study 35280720 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal laparoscopic extended lymph node dissection (LND) during extraperitoneal laparoscopic radical nephroureterectomy (RNU)
Number of subjects: 39
Study 35280786 — intervention group
Group type: EXPERIMENTAL
Intervention: whole-body PET/CT scan 40-60 min postinjection
Number of subjects: 19
Study 35280802 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) regimens
Number of subjects: 373
Study 35280802 — intervention group
Group type: COMPARATOR
Intervention: SOXA (apatinib in combination with S-1 and oxaliplatin) cohort
Number of subjects: 373
Study 35280910 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 1221
Study 35280910 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlin Definition of ARDS
Number of subjects: 1221
Study 35280910 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude-PaO
Number of subjects: 1221
Study 35281074 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 20
Study 35281074 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (ETA)
Number of subjects: 20
Study 35281856 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib (150 mg orally once a day for a 21-day cycle)
Number of subjects: 23
Study 35281992 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated atlas-based quantification procedure (AQP)
Number of subjects: 0
Study 35281992 — intervention group
Group type: COMPARATOR
Intervention: Manual delineation
Number of subjects: 0
Study 35281992 — intervention group
Group type: EXPERIMENTAL
Intervention: AQP
Number of subjects: 0
Study 35282037 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate (500 mg qd) plus pemetrexed (500 mg/m2)
Number of subjects: 21
Study 35282037 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate plus pemetrexed
Number of subjects: 21
Study 35282086 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib plus 5-fluorouracil (5-FU)
Number of subjects: 16
Study 35282136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetrombopag (5 mg orally once daily for up to 6 weeks)
Number of subjects: 37
Study 35282136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Number of subjects: 37
Study 35282170 — intervention group
Group type: EXPERIMENTAL
Intervention: Premium Monovision Group (PmG) - implantation of trifocal diffractive Panoptix IOL in the non-dominant eye and bifocal hybrid refractive-diffractive Restor IOL in the dominant eye.
Number of subjects: 120
Study 35282170 — intervention group
Group type: COMPARATOR
Intervention: Bilateral Myopic Monovision Group (MfG) - implantation of monofocal SN60WF IOL targeting -0.50 D in the dominant eye and -1.25 D myopia in the non-dominant eye.
Number of subjects: 120
Study 35282170 — intervention group
Group type: COMPARATOR
Intervention: Hybrid Monovision Group (HmG) - implantation of Panoptix in the non-dominant eye and SN60WF in the dominant eye.
Number of subjects: 120
Study 35282170 — intervention group
Group type: COMPARATOR
Intervention: Bilateral Trifocal Implantation Group - bilateral Panoptix implantation.
Number of subjects: 120
Study 35282383 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening left ventricular ejection fraction (LVEF) defined as an absolute decline ≥ 5% from baseline LVEF within 3 to 12 months after discharge.
Number of subjects: 1418
Study 35282383 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline left ventricular end-diastolic dimension (LVEDD), LVEF, high-density lipoprotein cholesterol (HDL-C), atrial fibrillation (AF), and diabetes mellitus (DM) as predictors of worsening LVEF.
Number of subjects: 1418
Study 35283064 — intervention group
Group type: EXPERIMENTAL
Intervention: Low LVEF1 group
Number of subjects: 644
Study 35283064 — intervention group
Group type: COMPARATOR
Intervention: High LVEF1 group
Number of subjects: 644
Study 35283104 — intervention group
Group type: EXPERIMENTAL
Intervention: benralizumab (30-mg subcutaneous dose)
Number of subjects: 29
Study 35283158 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy
Number of subjects: 0
Study 35283268 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered psychological intervention for chronic pain
Number of subjects: 85
Study 35283330 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (anti-IL-5RA)
Number of subjects: 7
Study 35283347 — intervention group
Group type: EXPERIMENTAL
Intervention: High early pregnancy body mass index
Number of subjects: 2363
Study 35283347 — intervention group
Group type: COMPARATOR
Intervention: Class II or III obesity
Number of subjects: 2363
Study 35283460 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative dosing forms of hydrocortisone
Number of subjects: 0
Study 35283460 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone receptor antagonists
Number of subjects: 0
Study 35283460 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen biosynthesis inhibitors
Number of subjects: 0
Study 35283460 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy vector
Number of subjects: 0
Study 35283693 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific membrane antigen- (PSMA-) targeted radioligand therapy (RLT)
Number of subjects: 21
Study 35283693 — intervention group
Group type: EXPERIMENTAL
Intervention: SUV parameters
Number of subjects: 21
Study 35283693 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric parameters
Number of subjects: 21
Study 35283693 — intervention group
Group type: EXPERIMENTAL
Intervention: SUVs
Number of subjects: 21
Study 35284589 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip arthroscopic surgery
Number of subjects: 60
Study 35284585 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 112
Study 35284585 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional distress
Number of subjects: 112
Study 35284585 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiophobia
Number of subjects: 112
Study 35284585 — intervention group
Group type: EXPERIMENTAL
Intervention: Widespread pain
Number of subjects: 112
Study 35284585 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy and emotional distress combined
Number of subjects: 112
Study 35284909 — intervention group
Group type: EXPERIMENTAL
Intervention: POM mHealth app
Number of subjects: 43
Study 35285015 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (DSF) 3 mg/kg, every 3rd day
Number of subjects: 0
Study 35285015 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (DSF) 10 mg/kg, every 3rd day
Number of subjects: 0
Study 35285015 — intervention group
Group type: COMPARATOR
Intervention: β-aminopropionitrile (BAPN) 100 mg/kg, daily
Number of subjects: 0
Study 35285405 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HF-RT) with nodal simultaneous integrated boost (nSIB) at a dose of 2.67 Gy x 15 fractions
Number of subjects: 0
Study 35285405 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HF-RT) with nSIB
Number of subjects: 0
Study 35285405 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-limiting toxicity (DLT)
Number of subjects: 0
Study 35285484 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab, chemotherapy, and external beam radiation therapy
Number of subjects: 51
Study 35285519 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam add-on therapy
Number of subjects: 2411
Study 35285747 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Therapists (RT)
Number of subjects: 445
Study 35285747 — intervention group
Group type: COMPARATOR
Intervention: Control group (physicians and nurses)
Number of subjects: 445
Study 35285786 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir 600 mg BID for 4 days
Number of subjects: 14
Study 35285786 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg BID for 5 days
Number of subjects: 14
Study 35285786 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir 600 mg BID with Maraviroc 300 mg BID for 7 days
Number of subjects: 14
Study 35285810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive test battery including EEG-based assessments and MRI imaging
Number of subjects: 600
Study 35285810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional data analysis
Number of subjects: 600